SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

SAN

74.115

-4.79%↓

SRT3

223.85

+3.01%↑

ORNBV.FI

68.5

+3.4%↑

Начало・Списък с акции・Fagron

Search

Fagron

Затворен

СекторЗдравеопазване

24 0.84

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

23.85

Максимум

24

Ключови измерители
By Trading Economics
Приходи	-99K 45M
Продажби	-98K 476M
P/E Средно за сектора	19.113 67.147
Дивидентна доходност	1.69
Марж на печалбата	9.55
Служители	4,193
EBITDA	11M 98M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+20.59% upside

Дивиденти
By Dow Jones
Дивидентна доходност Средно за сектора	1.69% 2.36%
Следващи печалби	30.07.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	109M 1.7B
Предишно отваряне	23.16
Предишно затваряне	24

Настроения в новините

By Acuity

50%

50%

176 / 347 Класиране в Healthcare

Fagron Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

4.05.2026 г., 22:17 ч. UTC

Печалби

Australia's Westpac Lifts Dividend as 1st Half Profit Rises 2.7%

4.05.2026 г., 23:47 ч. UTC

Печалби

Grab Holdings 1Q Adj EBITDA $154.0M Vs. $106.0M >GRAB

4.05.2026 г., 23:45 ч. UTC

Печалби

Grab Holdings 1Q Rev $955.0M Vs. $773.0M >GRAB

4.05.2026 г., 23:45 ч. UTC

Печалби

Grab Holdings 1Q Net $120.0M Vs. Net $10.0M >GRAB

4.05.2026 г., 23:40 ч. UTC

Пазарно говорене

Gold Steady Amid Likely Technical Recovery -- Market Talk

4.05.2026 г., 22:44 ч. UTC

Придобивния, сливания и поглъщания

Regis: Jim Beyer To Be Chief Executive of Combined Company

4.05.2026 г., 22:43 ч. UTC

Придобивния, сливания и поглъщания

Regis: Russell Clark To Be Nonexecutive Chairman of Combined Company

4.05.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Regis: Companies Expect to Realize Over A$500 Million in Corporate Tax Benefits

4.05.2026 г., 22:42 ч. UTC

Придобивния, сливания и поглъщания

Regis: Combined Company to Have Strong, Debt-Free Balance Sheet; Significant Cash Generation

4.05.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Regis: Combined Company to Have Annual Production of More Than 700,000 Oz

4.05.2026 г., 22:41 ч. UTC

Придобивния, сливания и поглъщания

Regis: Pro Forma Market Capitalization About A$10.7 Billion

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Shareholders to Own About 51% of Combined Company

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Board Unanimously Endorsed, Supported Deal

4.05.2026 г., 22:40 ч. UTC

Придобивния, сливания и поглъщания

Regis: Deal Unanimously Recommended by Vault Board

4.05.2026 г., 22:39 ч. UTC

Придобивния, сливания и поглъщания

Regis: Vault Shareholders to Receive 0.6947 New Shares in Regis For Each Vault One Held

4.05.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Regis Resources to Acquire All Ordinary Shares in Vault

4.05.2026 г., 22:38 ч. UTC

Придобивния, сливания и поглъщания

Regis Resources, Vault Minerals Agree to Merger of Equals

4.05.2026 г., 22:37 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- 2nd Update

4.05.2026 г., 22:26 ч. UTC

Печалби

Придобивния, сливания и поглъщания

Palantir Beats Forecasts With $1.63 Billion Quarter as Sales Accelerate -- Update

4.05.2026 г., 22:02 ч. UTC

Печалби

Australia's Westpac Lifts Dividend as 1H Profit Rises 2.7%

4.05.2026 г., 22:00 ч. UTC

Пазарно говорене

BOC's Macklem: Conditions To Dictate Fuel-Price Response -- Market Talk

4.05.2026 г., 21:52 ч. UTC

Печалби

Westpac 1H Net Profit Ex-Notable Items A$3.48B Vs. A$3.46B>WBC.AU

4.05.2026 г., 21:50 ч. UTC

Печалби

Westpac: Some Sectors More Affected Than Others>WBC.AU

4.05.2026 г., 21:50 ч. UTC

Печалби

Westpac: Economic Impact of Middle East Conflict to Continue Through Year>WBC.AU

4.05.2026 г., 21:49 ч. UTC

Печалби

Westpac 1H Provision for Expected Credit Losses A$4.68B Vs. A$4.58B>WBC.AU

4.05.2026 г., 21:44 ч. UTC

Печалби

Westpac 1H Australia Lending Up 8% on Year>WBC.AU

4.05.2026 г., 21:44 ч. UTC

Печалби

Westpac 1H Australia Business Lending Up 16% on Year>WBC.AU

4.05.2026 г., 21:43 ч. UTC

Печалби

Westpac 1H Core Net Interest Margin 1.78% Vs. 1.80%>WBC.AU

4.05.2026 г., 21:41 ч. UTC

Печалби

Westpac 1H Australian Home Lending Up 7% on Year Excluding RAMS Portfolio>WBC.AU

4.05.2026 г., 21:40 ч. UTC

Печалби

Westpac 1H Credit Impairment Charge 10 Bps of Average Loans Vs. 6 Bps>WBC.AU

Сравнение с други в отрасъла

Ценова промяна

Fagron Прогноза

Ценова цел

By TipRanks

20.59% нагоре

12-месечна прогноза

Среден 19.5 EUR 20.59%

Висок 19.5 EUR

Нисък 19.5 EUR

Според 1 анализатори от Wall Street, предложили 12-месечна ценова цел за Fagron през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

1 ratings

1

Купи

0

Задържане

0

Продай

Според 1 анализатори, дали борсови рейтинги на Fagron през последните 3 месеца.

Настроение

By Acuity

176 / 347 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

$

Относно Fagron

Fagron NV, a pharmaceutical compounding company, delivers personalized pharmaceutical care to hospitals, pharmacies, clinics, and patients worldwide. It operates in three segments: Essentials, Brands, and Compounding Services. The company also innovates concepts, vehicles, and formulations for pharmaceutical compounding. Its products include DiluCap, a line of excipients to compound every capsule formulation; Imuno TF Complex helps in regulation of immune responses; Pigmerise, a natural phytocomplex for hypopigmentation disorders; Pentravan uses for avoiding first-pass metabolism and preventing gastrointestinal erosion; Nourisil MD, a first line therapy for prevention and treatment of scars ang keloids; Neogen, a line of hair care products; TrichoConcept used to treat alopecia; Fagron Advanced Derma for basic skincare, compound pharmaceutical treatment, and individualized dermatological care; and SyrSpend SF that provides pharmaceutical stability, dosage consistency, and patient comfort. In addition, the company offers education and training program to prescribers and pharmacists through the Fagron Academy. The company was formerly known as Arseus NV and changed its name to Fagron NV in January 2015. Fagron NV was founded in 1990 and is based in Nazareth, Belgium.

Други акции от сектора

SAN

Sanofi SA

74.115

SRT3

Sartorius AG

223.85

ORNBV.FI

Orion Oyj (Class B)

68.5

Live chat